SAN DIEGO, Sept. 30, 2020 /PRNewswire/ -- IRISYS LLC, a
pharmaceutical contract manufacturing and development organization
(CDMO), announced its third contract for production and
manufacturing in partnership with TFF Pharmaceuticals, Inc., a
clinical-stage biopharmaceutical company located in
Austin, TX. Most recently,
TFF Pharmaceuticals contracted with IRISYS to manufacture an
inhalable lung medication with the potential to treat COVID-19.
A publicly traded company (NASDAQ: TFFP), TFF
Pharmaceuticals researches and innovates drug products based
on its patented Thin Film Freezing, or TFF, technology platform.
This freezing process creates dry powder formulations with
properties ideal for inhalation and can potentially target
SARS-CoV-2, the disease caused by COVID-19, inside the lungs by
delivering medication directly to the infection site. TFF has
compounds under development that can be used to treat
challenging-to-manage lung conditions such as Invasive Pulmonary
Aspergillosis, or IPA, and COVID-19.
TFF found IRISYS to be a superior partner for the transfer
of its technology to IRISYS' labs. IRISYS will be responsible for
the initial production and testing of TFF's investigational powder
product for inhalation. IRISYS was able to help adapt the process
to the needs of the project and to establish a robust manufacturing
process suitable for clinical trial materials preparation.
"The most important part of this project is that we are not
just helping develop a new formulation, but a new technology. With
the versatility of this process, any lung therapeutic could
potentially be applicable," - JJ Sigler, IRISYS
Scientist
The TFF platform was designed to improve solubility of poorly
water-soluble drugs generally, and the technology is particularly
useful in generating dry powder particles with properties targeted
for inhalation delivery, especially to the deep lung, an area of
extreme interest in respiratory medicine. The TFF process involves
dissolving the drug in a solvent system, and then flash freezing
the drug substance. The frozen powder is lyophilized, resulting in
a "Brittle Matrix Particle," which possesses low bulk density, high
surface area, and typically an amorphous morphology, allowing the
particles to supersaturate when contacting the target site, such as
lung tissue. Based upon laboratory experiments, the aerodynamic
properties of the particles are such that the portion of drug
deposited to the deep lung has the potential to reach as high as
75%.
Heather Emerson-Young
Digital Marketing Strategist
IRISYS LLC
hemerson@irisys.com
858-281-7920
View original content to download
multimedia:http://www.prnewswire.com/news-releases/irisys-llc-signs-a-third-contract-with-tff-pharma-to-produce-medication-to-treat-lung-conditions-including-covid-19-301142192.html
SOURCE IRISYS LLC